{"organizations": [], "uuid": "6a05da44cc5c4812263f2b88f0be908ade08704a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mirati-therapeutics-announces-prog/brief-mirati-therapeutics-announces-progress-of-lead-programs-idUSASC09X56", "country": "US", "domain_rank": 408, "title": "BRIEF-Mirati Therapeutics Announces Progress Of Lead Programs", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.532, "site_type": "news", "published": "2018-04-25T04:43:00.000+03:00", "replies_count": 0, "uuid": "6a05da44cc5c4812263f2b88f0be908ade08704a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mirati-therapeutics-announces-prog/brief-mirati-therapeutics-announces-progress-of-lead-programs-idUSASC09X56", "ord_in_thread": 0, "title": "BRIEF-Mirati Therapeutics Announces Progress Of Lead Programs", "locations": [], "entities": {"persons": [{"name": "sitravatinib", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-mirati therapeutics announces progress of lead programs", "sentiment": "negative"}, {"name": "mirati therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Mirati Therapeutics Inc:\n* MIRATI THERAPEUTICS ANNOUNCES PROGRESS OF LEAD PROGRAMS AND PROVIDES UPDATED POSITIVE CLINICAL TRIAL RESULTS FOR IMMUNO-ONCOLOGY COMBINATION TRIALS\n* MIRATI THERAPEUTICS INC - MRTX849 ON TRACK FOR AN INVESTIGATIONAL NEW DRUG SUBMISSION IN Q4 OF 2018\n* MIRATI THERAPEUTICS - SITRAVATINIB BEING EVALUATED IN PHASE 2 STUDY IN COMBINATION WITH NIVOLUMAB HAS BEEN WELL-TOLERATED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T04:43:00.000+03:00", "crawled": "2018-04-25T14:51:05.002+03:00", "highlightTitle": ""}